WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
76ers president Daryl Morey has big plans to build NBA title team around Embiid and MaxeyJohn Swinney is crowned as SNP leaderAnaheim Ducks goaltending coach Sudarshan Maharaj declared cancerRedfin agrees to pay $9.25 million to settle real estate broker commission lawsuitsNo, France did not deploy troops to fight with Ukraine against RussiaTwo suspects arrested in fatal shooting on Delaware college campus are not students, police sayNonprofit Chicago production house Invisible Institute wins 2 Pulitzer PrizesEdward Olivares' grand slam and Mitch Keller's complete game lead Pirates over Angels 4Jewish leaders demand newlyShocking moment Pennsylvania man pulls a gun on pastor in front of horrified congregation
1.9842s , 6490.96875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Grandeur news portal